ADXS: Ayala Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) n/a
Enterprise Value ($M) n/a
Book Value ($M) 0.00
Book Value / Share n/a
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share n/a
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.00
Liabilities 0.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Redmile Group, LLC 1.90 -36.51
02-12 13D/A Israel Biotech Fund I, L.P. 71.63 -9.75
02-12 13G/A Schindel Yair Chaim 1.31 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRAN
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)

Similar Companies
ACUR – Acura Pharmaceuticals, Inc. ACUT – AccuStem Sciences, Inc.
ADIA – Adia Nutrition, Inc. AFFY – Affymax, Inc.
AGTX – Agentix Corp.


Financial data and stock pages provided by
Fintel.io

Finpedia: Advaxis